RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Service Contact Center

Contact details for order support and technical support.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Service Contact Center

Contact details for order support and technical support.

Learning Hub

Explore resources, including product documentation, software, webinars, videos, virtual demos and more.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Quality & Safety Data

Find quality and safety documentation for your products.

Product & Technical Support

Find out which products work together, search our FAQ database and troubleshoot.

Ordering from QIAGEN

Learn about easy ordering options that offer fast and reliable delivery.

Key Figures

Home  >  Investor Relations  >  At a glance  >  Key Figures
Years ended December 31
$1,000 except per share data 2020 2019 2018 2017 2016
Result
Net sales 1,870,346 1,526,424 1,501,848 1,417,536 1,337,991
Operating income (loss) 386,431 (26,136) 266,581 153,419 98,827
Net income (loss)1 359,188 (41,455) 190,380 40,394 80,404
Basic earnings (loss) per share (EPS)1 1.57 (0.18) 0.84 0.18 0.34
Diluted earnings (loss) per share (EPS)1 1.53 (0.18) 0.82 0.17 0.34
Number of shares (in thousands)
Common shares used to compute basic earnings per share2 228,427 226,777 226,640 228,074 234,800
Common shares used to compute diluted earnings per share3 234,214 226,777 233,456 233,009 238,993
Cash flow
Cash flow from operations 457,806 330,843 359,496 286,779 341,602
Capital expenditures for property, plant and equipment 132,787 117,950 109,773 90,081 74,536
Free cash flow4 325,019 212,893 249,723 196,698 267,066

As of December 31

Balance sheet
Total assets 5,912,530 5,235,616 5,748,332 5,038,516 4,308,194
Cash, cash equivalents and restricted cash 597,984 629,390 1,159,079 657,714 439,180
Total long-term liabilities, including current portion 2,542,144 2,032,924 2,644,373 2,174,087 1,393,668
Total equity 2,797,839 2,536,591 2,634,970 2,540,996 2,607,096

Please visit Financial Reports for more information.

1Attributable to the owners of QIAGEN N.V.

2Weighted average number of common shares used to compute basic earnings per common share

3Weighted average number of common shares used to compute diluted earnings per common share

4Free cash flow is calculated from cash provided by operations reduced by purchases of property, plant and equipment